Oracle (NYSE:ORCL) is reporting its strongest revenue growth in over 15 years, supported by surging demand for AI infrastructure. This rapid growth coincides with deeply negative free cash flow and rising debt, as the company continues to pay a sizable dividend. The tension between heavy AI investment, expanding contracted backlog and ongoing dividend commitments is raising new questions about the...
Oracle (NYSE:ORCL) is reporting its strongest revenue growth in over 15 years, supported by surging demand for AI infrastructure. This rapid growth coincides with deeply negative free cash flow and rising debt, as the company continues to pay a sizable dividend. The tension between heavy AI investment, expanding contracted backlog and ongoing dividend commitments is raising new questions about the sustainability of Oracle's capital return policy. Oracle enters this phase of AI driven growth...
Monks, the unitary operating brand of S4 Capital plc, has appointed Alex Oberberg as Chief Revenue Officer (CRO) for EMEA. Effective immediately, Oberberg will lead the region's commercial strategy, focusing on scaling Monks' high-velocity, AI-driven systems for global enterprise clients.
Monks, the unitary operating brand of S4 Capital plc, has appointed Alex Oberberg as Chief Revenue Officer (CRO) for EMEA. Effective immediately, Oberberg will lead the region's commercial strategy, focusing on scaling Monks' high-velocity, AI-driven systems for global enterprise clients.
halbergman/E+ via Getty Images Fermi ( FRMI ) stock plunged after the data center REIT reported a GAAP net loss of $486.4M, or $1.13 per share, for the period of January 10, 2025, (inception) to December 31, 2025. Shares were 10.84% lower to $5.51 before the U.S. market open on Monday. The company, co-founded by former U.S. Energy Secretary Rick Perry, started trading at $25 per share on the Nasda...
halbergman/E+ via Getty Images Fermi ( FRMI ) stock plunged after the data center REIT reported a GAAP net loss of $486.4M, or $1.13 per share, for the period of January 10, 2025, (inception) to December 31, 2025. Shares were 10.84% lower to $5.51 before the U.S. market open on Monday. The company, co-founded by former U.S. Energy Secretary Rick Perry, started trading at $25 per share on the Nasdaq in its market debut on October 1, 2025. At the end of the fourth quarter, the company had $408.5M of cash and cash equivalents. "Our first year proved that building America's AI energy backbone demands more than capital - it demands relentless execution, a workforce willing to operate at startup pace on an industrial scale, and partners across government, manufacturing, and construction who share our sense of urgency," said Fermi Founder and CEO Toby Neugebauer in a shareholders letter. "We understand the question at the top of every shareholder's mind: when will Fermi announce its first definitive tenant lease? Our answer has remained deliberate and consistent - we will move forward only when the terms, the partner, and the capital structure meet the disciplined capital and risk standards we require for long-term value creation," said the letter. "Our focus is not on whether we will secure a tenant, but on securing the right one," noted the CEO in the letter. More on Fermi Inc. Fermi: Pre-Revenue REIT Needs More Capital Mid-Cap real estate stocks ranked by quant ratings after earnings season Seeking Alpha’s Quant Rating on Fermi Inc. Historical earnings data for Fermi Inc. Financial information for Fermi Inc.
Shoppers pass fruit and vegetable stalls in the Bauveau Market in Paris, France, on Wednesday, Feb. 15, 2023. Bloomberg | Bloomberg | Getty Images Economic and consumer confidence plummeted in Europe in March, according to official data released on Monday, in the latest evidence of how the Iran war is upending growth and inflation expectations. Preliminary data from the European Commission shows e...
Shoppers pass fruit and vegetable stalls in the Bauveau Market in Paris, France, on Wednesday, Feb. 15, 2023. Bloomberg | Bloomberg | Getty Images Economic and consumer confidence plummeted in Europe in March, according to official data released on Monday, in the latest evidence of how the Iran war is upending growth and inflation expectations. Preliminary data from the European Commission shows economic sentiment declined in both the EU (down 1.5 points from the previous month to 96.7) and the euro area (down 1.6 points to 96.6) in March. The figures, measuring economic sentiment across five key sectors of the European economy, also reveal employment expectations are under pressure across the EU and euro zone. Employers in the retail trade, services and industry sectors are all adjusting their employment plans against a backdrop of ongoing war in the Middle East. watch now VIDEO 4:44 04:44 Iran conflict enters fifth week as Houthi strikes open new front Squawk Box Europe The slump adds to a deterioration seen in February, but the Commission warned the latest data prints showed a "marked deterioration of economic sentiment in March", which had driven both economic sentiment and employment expectations "away from their long-term average of 100." Consumer confidence also fell sharply to its lowest level since Oct. 2023, "driven by a dramatic decline in consumers' expectations for the overall economic situation in their country." "Consumers also became markedly more pessimistic about their household's future financial situation and less prone to make major purchases over the next 12 months," the Commission added. It follows separate data showing euro zone private sector output fell to a 10-month low and toward contraction territory in March, raising fears of looming "stagflation". In revised forecasts released on March 19, the European Central Bank now expects economic growth of 0.9% in 2026, and headline inflation to average 2.6% this year. ECB President Christine Lag...
bauwimauwi/iStock via Getty Images Introduction Back when I last covered Celsius Holdings ( CELH ), I highlighted their undervaluation and strong performance despite the consumer environment continuing to be weak, while mentioning that deepening their PepsiCo ( PEP ) partnership enhances their competitive positioning and allows them to develop Alani and now Rockstar as well. Following a strong Q4 ...
bauwimauwi/iStock via Getty Images Introduction Back when I last covered Celsius Holdings ( CELH ), I highlighted their undervaluation and strong performance despite the consumer environment continuing to be weak, while mentioning that deepening their PepsiCo ( PEP ) partnership enhances their competitive positioning and allows them to develop Alani and now Rockstar as well. Following a strong Q4 and 2025 marked by excellent performance, especially from Alani, I'm upgrading Celsius to a Strong Buy, as their valuation is now reflecting a deep discount to even a conservative fair value estimate, standing to benefit significantly from a potential consumer recovery alongside growing their brand both domestically and internationally. Fundamentals Improving as Deals Advance Celsius Holdings IR Celsius reported a strong Q4 and 2025 overall, beating the market's revenue and EPS estimates by a bit, with the Alani Nu and Rockstar deals strengthening their portfolio ( recently highlighting that Alani is not cannibalizing Celsius much - which is an argument they had since the beginning, now starting to get proven by data) and boosting their growth significantly while the international expansion advances rapidly. The company's free cash flow grew significantly to $323.38 million in 2025 compared to $239.51 million in 2024 and $123.79 million in 2023, as the company's pivot into positive cash flows is ramping up alongside their business. Celsius Holdings IR As they show, the company is once again a major contributor to the entire category's growth, with their Q4 growth contributing to a whopping 33% of the category's increase, while their combined US market shares sum up to nearly 20% now, while Alani is growing significantly and still having plenty of room to expand domestically and internationally as well, Rockstar Energy's integration is progressing and expected to be completed in the first half of 2026, with the CFO mentioning the following expectations for this year during t...
German inflation accelerated sharply in March after the Iran war boosted energy costs, supporting the idea that the European Central Bank will have to raise interest rates. Consumer prices rose 2.8% from a year ago — faster than February’s 2% advance — the statistics office said Monday. That’s the highest level in more than a year and matches the median estimate in a Bloomberg survey. Energy costs...
German inflation accelerated sharply in March after the Iran war boosted energy costs, supporting the idea that the European Central Bank will have to raise interest rates. Consumer prices rose 2.8% from a year ago — faster than February’s 2% advance — the statistics office said Monday. That’s the highest level in more than a year and matches the median estimate in a Bloomberg survey. Energy costs soared by 7.2% — the first increase since December 2023. A gauge stripping out volatile items like fuel and food was unchanged at 2.5%. With the fighting in the Middle East now in its fifth week, the effect of costlier oil and gas is showing up in European prices and consumers’ views on where inflation is headed. While ECB President Christine Lagarde has vowed to act decisively and swiftly if needed, officials say they won’t rush as they assess the full consequences. Money markets anticipate a rapid reaction and are leaning toward a rate hike already at April’s meeting. They’re pricing as many as three moves over the whole year. Germany’s numbers follow a jump in Spanish inflation , to 3.3%, though the increase fell short of analyst estimates. Figures from France and Italy are due Tuesday, along with a reading for the euro zone that’s set to hit 2.6% — the highest since July 2024. Read More: Biggest Euro-Zone Price Jump Since 2022 Seen in First G-20 Data There are signs in Germany that some don’t expect a speedy resolution to the energy issues, with a survey by the Ifo institute published earlier Monday showing significantly more firms are preparing to raise prices. A separate European Commission poll put inflation expectations among consumers at their highest level since 2022. Policymakers have a “duty” to avoid such beliefs becoming entrenched, French central-bank chief Francois Villeroy de Galhau told La Stampa. Greece’s Yannis Stournaras warned that a lengthier war could trigger stagflation and a deviation from the ECB’s baseline scenario, which envisages prices rising...
Bicara Therapeutics press release ( BCAX ): Q4 GAAP EPS of -$0.68. Cash, Cash Equivalents and Marketable Securities: As of December 31, 2025, Bicara had cash, cash equivalents and marketable securities of $414.8 million, compared to $489.7 million in cash and cash equivalents as of December 31, 2024. An additional $161.8 million in net proceeds was raised via an oversubscribed public offering in t...
Bicara Therapeutics press release ( BCAX ): Q4 GAAP EPS of -$0.68. Cash, Cash Equivalents and Marketable Securities: As of December 31, 2025, Bicara had cash, cash equivalents and marketable securities of $414.8 million, compared to $489.7 million in cash and cash equivalents as of December 31, 2024. An additional $161.8 million in net proceeds was raised via an oversubscribed public offering in the first quarter of 2026. Research and Development Expenses: Research and development expenses were $33.0 million for the fourth quarter of 2025 as compared to $19.9 million for the fourth quarter of 2024, and $125.1 million for the full year 2025 as compared to $63.6 million for the full year 2024. The increase was primarily due to costs associated with ongoing pivotal Phase 2/3 clinical trial, FORTIFI-HN01, as well as the Company’s ongoing Phase 1/1b dose expansion cohorts, and an increase in personnel costs. More on Bicara Therapeutics Bicara Therapeutics Inc. (BCAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma - Slideshow Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma Transcript Bicara Therapeutics prices offering to raise $150M Seeking Alpha’s Quant Rating on Bicara Therapeutics